Fibroblast-specific perturbation of transforming growth factor β signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: Exaggerated response to alveolar epithelial injury in a novel mouse model

Arthritis and Rheumatism

Volumn 58, Issue 4, 2008, Pages 1175-1188

  Hoyles, Rachel K ^a,b   Khan, Korsa ^a   Shiwen, Xu ^a   Howat, Sarah L ^a   Lindahl, Gisela E ^a   Leoni, Patricia ^a   Du Bois, Roland M ^b   Wells, Athol U ^b   Black, Carol M ^a   Abraham, David J ^a   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCHEMISTRY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DISEASE PREDISPOSITION; DISEASE SEVERITY; ELECTRON MICROSCOPY; FIBROBLAST; HISTOPATHOLOGY; HYPERPLASIA; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG INJURY; MOUSE; MYOFIBROBLAST; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCLERODERMA; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BLEOMYCIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FIBROBLASTS; IRRITANTS; MICE; MICE, TRANSGENIC; PULMONARY ALVEOLI; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 42449125545     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23379     Document Type: Article

References (49)

1. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
2. Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-11.
3. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor β1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994;37:278-88.
4. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, et al. Dysregulation of transforming growth factor β signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002;46:1857-65.
5. Corrin B, Butcher D, McAnulty BJ, du Bois RM, Black CM, Laurent GJ, et al. Immunohistochemical localization of TGFβ1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24:145-50.
6. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 2005;52:865-76.
7. Fanti S, De Fabritiis A, Aloisi D, Dondi M, Marengo M, Compagnone G, et al. Early pulmonary involvement in systemic sclerosis assessed by technetium-99m-DTPA clearance rate. J Nucl Med 1994;35:1933-6.
8. Yanaba K, Hasegawa M, Hamaguchi Y, Fujimoto M, Takehara K, Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003;21:429-36.
9. Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000;200:196-201.
10. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51.
11. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, et al. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007;56:334-44.
12. Denton CP, Zheng B, Shiwen X, Zhang Z, Bou-Gharios G, Eberspaecher H, et al Activation of a fibroblast-specific enhancer of the proα2(I) collagen gene in tight-skin mice. Arthritis Rheum 2001;44:712-22.
13. Denton CP, Zheng B, Evans LA, Shi-Wen X, Ong VH, Fisher I, et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003;278:25109-19.
14. Denton CP, Lindahl GE, Khan K, Shiwen X, Ong VH, Gaspar NJ, et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRII[symbol:SymbolPS/68]k). J Biol Chem 2005;280:16053-65.
15. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBRI or TGFBR2. Nat Genet 2005;37:275-81.
16. Underwood SL, Raeburn D, Lawrence C, Foster M, Webber S, Karlsson JA. RPR 106541, a novel, airways-selective glucocorticoid: effects against antigen-induced CD4+ T lymphocyte accumulation and cytokine gene expression in the Brown Norway rat lung. Br J Pharmacol 1997;122:439-46.
17. Ponticos M, Abraham D, Alexakis C, Lu QL, Black C, Partridge T, et al. Col1a2 enhancer regulates collagen activity during development and in adult tissue repair. Matrix Biol 2004;22:619-28.
18. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991;114:1285-94.
19. Wert SE, Dey CR, Blair PA, Kimura S, Whitsett JA. Increased expression of thyroid transcription factor-1 (TTF-1) in respiratory epithelial cells inhibits alveolarization and causes pulmonary inflammation. Dev Biol 2002;242:75-87.
20. Plataki M, Koutsopoulos AV, Darivianaki K, Delides G, Siafakas NM, Bouros D. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 2005;127:266-74.
21. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007;56:2005-12.
22. Jimenez SA, Christner PJ. Murine animal models of systemic sclerosis [review]. Curr Opin Rheumatol 2002;14:671-80.
23. Christner PJ, Jimenez SA. Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches [review]. Curr Opin Rheumatol 2004;16:746-52.
24. Borzone G, Moreno R, Urrea R, Meneses M, Oyarzun M, Lisboa C. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;163:1648-53.
25. Denton CP, Abraham DJ. Transgenic analysis of scleroderma: understanding key pathogenic events in vivo [review]. Autoimmun Rev 2004;3:285-93.
26. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models [review]. Trends Immunol 2005;26:587-95.
27. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999;163:5693-9.
28. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004;50:1319-31.
29. Gardi C, Martorana PA, Calzoni P, van Even P, de Santi MM, Cavarra E, et al. Lung collagen synthesis and deposition in tight-skin mice with genetic emphysema. Exp Mol Pathol 1992;56:163-72.
30. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers [review]. Proc Am Thorac Soc 2006;3:364-72.
31. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL. Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol 2001;54:132-8.
32. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:350-6.
33. Uhal BD, Joshi I, True AL, Mundle S, Raza A, Pardo A, et al. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 1995;269:L819-28.
34. Uhal BD, Joshi I, Hughes WF, Ramos C, Pardo A, Selman M. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998;275:L1192-9.
35. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor β1-induced pulmonary fibrosis. J Exp Med 2004;200:377-89.
36. Hagimoto N, Kuwano K, Inoshima I, Yoshimi M, Nakamura N, Fujita M, et al. TGF-β1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 2002;168:6470-8.
37. Wallach-Dayan SB, Izbicki G, Cohen PY, Gerstl-Golan R, Fine A, Breuer R. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway. Am J Physiol Lung Cell Mol Physiol 2006;290:L790-6.
38. Fadok VA, Bratton DL, Konowal A, Freed PW, Wetcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGFβ, PGE2, and PAF. J Clin Invest 1998;101:890-8.
39. Ramos C, Montano M, Becerril C, Cisneros-Lira J, Barrera L, Ruiz V, et al. Acidic fibroblast growth factor decreases α-smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2006;291:L871-9.
40. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T. Transforming growth factor-β1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 2001;163:152-7.
41. Deterding RR, Havill AM, Yano T, Middleton SC, Jacoby CR, Shannon JM, et al. Prevention of bleomycin-induced lung injury in rats by keratinocyte growth factor. Proc Assoc Am Physicians 1997;109:254-68.
42. Marchand-Adam S, Plantier L, Bernuau D, Legrand A, Cohen M, Marchal J, et al. Keratinocyte growth factor expression by fibroblasts in pulmonary fibrosis: poor response to interleukin-1β. Am J Respir Cell Mol Biol 2005;32:470-7.
43. Zhang F, Nielsen LD, Lucas JJ, Mason RJ. Transforming growth factor-β antagonizes alveolar type II cell proliferation induced by keratinocyte growth factor. Am J Respir Cell Mol Biol 2004;31:679-86.
44. Bao S, Wang Y, Sweeney P, Chaudhuri A, Doseff AI, Marsh CB, et al. Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005;288:L36-42.
45. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6.
46. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F. Konig G, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996;154:400-6.
47. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-28.
48. Sheppard D. Transforming growth factor β: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 2006;3:413-7.
49. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993;90:770-4.